4//SEC Filing
Kassberg Thomas Richard 4
Accession 0000950170-25-032802
CIK 0001515673other
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 8:19 PM ET
Size
8.5 KB
Accession
0000950170-25-032802
Insider Transaction Report
Form 4
Kassberg Thomas Richard
CBO & Senior Vice President
Transactions
- Award
Common Stock
2025-03-01+18,443→ 271,266 total - Tax Payment
Common Stock
2025-03-03$42.92/sh−508$21,803→ 264,730 total - Sale
Common Stock
2025-03-03$42.10/sh−6,028$253,779→ 265,238 total
Footnotes (5)
- [F1]Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric.
- [F2]Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
- [F5]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Documents
Issuer
Ultragenyx Pharmaceutical Inc.
CIK 0001515673
Entity typeother
Related Parties
1- filerCIK 0001303811
Filing Metadata
- Form type
- 4
- Filed
- Mar 3, 7:00 PM ET
- Accepted
- Mar 4, 8:19 PM ET
- Size
- 8.5 KB